Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
